ELUSYS THERAPEUTICS
Elusys Therapeutics is a privately-held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious disease. The Company has pioneered the development of a rapid injection, anti-toxin antibody, Anthim:registered:, for the prophylaxis and treatment of anthrax disease following a biowarfare attack. Anthim has consistently demonstrated significant efficacy in multiple non-clinical animal studies and has been successfully evaluated in two clinical safety trials.
ELUSYS THERAPEUTICS
Industry:
Biotechnology
Founded:
1998-01-01
Address:
Pine Brook, New Jersey, United States
Country:
United States
Website Url:
http://www.elusys.com
Total Employee:
11+
Status:
Active
Contact:
9738080322
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins
Similar Organizations
LEAD Therapeutics
LEAD Therapeutics is a drug discovery company developing small molecule IND candidates for the treatment of cancer and infectious diseases.
Nereus Pharmaceuticals
Nereus Pharmaceuticals engages in the discovery and development of therapeutics for the treatment of infectious diseases and inflammation.
Rytol Pharmaceutical
Rytol Pharma is a leading biopharma company focused on the development of treatments for cardiovascular, liver infectious diseases.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.elusys.com
- Host name: vps21625.dreamhostps.com
- IP address: 67.205.57.132
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Elusys Therapeutics"
About - Elusys
Elusys Therapeutics leverages immune-stimulatory and immune-derived therapies to combat infectious disease. Our anthrax antitoxin obiltoxaximab, licensed as ANTHIM® in the United States and Canada, is a medical …See details»
Elusys Therapeutics - Crunchbase Company Profile
Elusys Therapeutics is a privately-held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious disease. The Company has pioneered the development of a rapid injection, …See details»
Management Team - Elusys
Jeffrey Wolf is the founder and CEO of Elusys. He also founded Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies founded …See details»
Elusys Therapeutics - Wikipedia
Elusys Therapeutics is a biopharmaceutical company founded in Pine Brook, New Jersey in 1998. The company specializes in the development of antibodies for the treatment infectious diseases. The antibodies are developed from protein complexes called heteropolymers which can bind to specific pathogens on one side and red blood cells on the other side. The pathogens will be dragged to the liver where they will be destroyed. The antibodies have a …See details»
Elusys Therapeutics, Inc. - LinkedIn
Elusys Therapeutics is dedicated to delivering innovative medical countermeasures that enable fast, effective, and durable protection against infectious agents. Our goal is to accelerate the ...See details»
Elusys Company Profile 2024: Valuation, Funding & Investors
Elusys General Information Description. Developer of antibody therapeutics designed to treat life-threatening infectious diseases. The company's therapeutics treat anthrax exposure following …See details»
Elusys Therapeutics, Inc. Company Profile | Parsippany, NJ ...
Company Description: Elusys Therapeutics is recruiting antibodies in its anti-terrorism campaign. The company develops antibody therapies for a variety of targets, including anthrax. Its lead …See details»
Elusys Therapeutics, Inc. - Devex
Learn more about Elusys Therapeutics, Inc.'s jobs, projects, latest news, contact information and geographical presence. Elusys Therapeutics is a NightHawk Biosciences company that …See details»
Elusys Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Reduces operating expenses by 34% and net loss by 64%DURHAM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius” or “the …See details»
NightHawk shifts focus to contract development and …
Dec 13, 2023 Morrisville-based NightHawk Biosciences is changing direction – and business strategy.The company has announced the divestiture of its biodefense subsidiary, Elusys Therapeutics, and other related assets to …See details»
Heat Biologics Announces Planned Acquisition of Elusys
Dec 21, 2021 Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S., Canada, Europe and the United Kingdom. December 21, 2021 07:30 ET | Source: Heat BiologicsSee details»
Obiltoxaximab Receives Marketing Authorization From European …
Dec 2, 2020 /CNW/ -- Elusys Therapeutics, Inc. (Elusys) today announced that the European Commission has approved obiltoxaximab, the company's monoclonal antibody (mAb)...See details»
Products - Elusys
Elusys has been awarded over $450 million in procurement and development contracts by the Biomedical Advanced Research and Development Authority (BARDA), the National Institute of …See details»
NightHawk Biosciences Shifts into a Pure-Play Large-Molecule …
Dec 20, 2023 Following the divestiture of its Elusys subsidiary and other non-core assets, NightHawk Biosciences will transform into a pure-play large-molecule CDMO. ... announced in …See details»
Elusys Therapeutics Receives Health Canada Approval For
Aug 12, 2020 /CNW/ -- Elusys Therapeutics, Inc. ... Organization Profile. Elusys Therapeutics, Inc. Contact Cision. 866-245-2317 from 8 AM - 10 PM ET Contact Us Become a Client; …See details»
Elusys Products
We develop antibody therapeutics for the treatment of infectious disease. ANTHIM ® (obiltoxaximab) U.S. Prescribing InformationU.S. Prescribing Information Canadian …See details»
2022-04-20 - Elusys
DURHAM, N.C., April 20, 2022 – (GLOBE NEWSWIRE) – Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed “NightHawk Biosciences”), a fully-integrated biopharmaceutical …See details»
NightHawk divesting Elusys assets to focus on CDMO contracts
NightHawk also intends to divest its Elusys subsidiary and related assets to a private company started by its CEO. Under the deal, the private company will pay NightHawk $500K upfront, …See details»
News & Media - Elusys
Dec 12, 2023 Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics. April 20, 2022. Elusys Therapeutics Finalizes HHS Contract to Deliver …See details»